Your browser is no longer supported. Please, upgrade your browser.
SIGA SIGA Technologies, Inc. daily Stock Chart
SIGA Technologies, Inc.
Index- P/E1.04 EPS (ttm)5.13 Insider Own2.70% Shs Outstand83.12M Perf Week-2.57%
Market Cap441.37M Forward P/E- EPS next Y- Insider Trans- Shs Float54.20M Perf Month-11.20%
Income421.80M PEG1.04 EPS next Q- Inst Own30.10% Short Float3.25% Perf Quarter-28.24%
Sales477.10M P/S0.93 EPS this Y- Inst Trans0.45% Short Ratio9.26 Perf Half Y-0.19%
Book/sh1.27 P/B4.18 EPS next Y- ROA277.20% Target Price11.00 Perf Year-14.35%
Cash/sh1.21 P/C4.38 EPS next 5Y1.00% ROE-324.10% 52W Range4.68 - 8.47 Perf YTD-32.78%
Dividend- P/FCF- EPS past 5Y77.90% ROI249.60% 52W High-37.31% Beta0.43
Dividend %- Quick Ratio10.40 Sales past 5Y144.00% Gross Margin80.00% 52W Low13.46% ATR0.29
Employees41 Current Ratio10.70 Sales Q/Q14.30% Oper. Margin74.40% RSI (14)30.03 Volatility5.63% 5.28%
OptionableYes Debt/Eq0.73 EPS Q/Q497.40% Profit Margin88.40% Rel Volume0.64 Prev Close5.25
ShortableYes LT Debt/Eq0.73 EarningsMay 03 AMC Payout0.00% Avg Volume190.06K Price5.31
Recom- SMA20-7.55% SMA50-14.54% SMA200-18.63% Volume121,684 Change1.14%
Mar-26-19 05:33PM  6 Low Price-Earnings Stocks
Feb-21-19 07:30AM  SIGA to Present at the 8th Annual SVB Leerink Global Healthcare Conference on March 1, 2019 GlobeNewswire
Nov-15-18 08:15AM  Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-06-18 03:35PM  How Immersion Corporation (IMMR) Stacks Up Against Its Market Cap Peers Insider Monkey
Nov-01-18 07:30AM  SIGA Announces Priority Review Voucher Transaction Totaling $80 Million GlobeNewswire
Oct-09-18 12:00PM  Orchestra BioMed Adds Three Industry Leaders to Strategic Advisory Board GlobeNewswire
Oct-04-18 07:30AM  SIGA Enters into Cooperative Research and Development Agreement with U.S. Army Medical Research Institute of Infectious Disease to Evaluate the Efficacy of TPOXX® as a Post-Exposure Prophylactic for Smallpox GlobeNewswire
Sep-27-18 07:30AM  SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018 GlobeNewswire
Sep-17-18 07:30AM  SIGA Technologies to Host Business Update Webcast on September 27, 2018 GlobeNewswire
Sep-13-18 04:01PM  SIGA Technologies to Ring the Nasdaq Opening Bell on Friday, September 14, 2018 GlobeNewswire
Sep-10-18 05:50PM  SIGA Technologies Awarded BARDA Contract for TPOXX® GlobeNewswire
Jul-16-18 10:42AM  Siga Continues Rally After FDA Approves Smallpox Drug Benzinga
Jul-13-18 03:47PM  U.S. Food and Drug Administration Approves SIGA Technologies TPOXX® (tecovirimat) for the Treatment of Smallpox GlobeNewswire +17.79%
03:33PM  SIGA Technologies shares rise 10% on approval of first-ever smallpox therapy MarketWatch
Jul-05-18 07:30AM  Pivotal Trial Data for SIGA Technologies Oral TPOXX® Published in the New England Journal of Medicine GlobeNewswire
May-31-18 07:30AM  SIGA to Present at the Jefferies Global Healthcare Conference on June 8, 2018 GlobeNewswire
May-03-18 08:31AM  Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss Benzinga
May-02-18 07:41AM  Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings Benzinga +10.36%
May-01-18 04:03PM  SIGA Technologies Announces Favorable Outcome of Advisory Committee In Support of TPOXX® GlobeNewswire
07:05AM  SIGA Technologies Stock Trading Halted Today; FDA Advisory Committee is Scheduled to Review New Drug Application of TPOXX® GlobeNewswire
Feb-27-18 08:30AM  Emerging Developments: New Research on Siga Technologies and Tropicana Entertainment - A Look Ahead into 2018 ACCESSWIRE
Aug-25-17 10:58AM  SIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York, New York.